• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

NLA: Data on ApoC3 Inhibitors Shows Promise Across a Spectrum of Hypertriglyceridemic Disorders

by MM360 Staff | May 31, 2025 | Myeloma News

Source: Pharmacy Times articles Emerging therapies targeting apolipoprotein C-III (ApoC3) are demonstrating significant promise in lowering triglycerides and reducing cardiovascular risk for patients with severe hypertriglyceridemia and rare disorders, such as...

Novel Agents, Promising Data: The Evolving Landscape of Oncology Care

by MM360 Staff | May 31, 2025 | Myeloma News

Source: Pharmacy Times articles Post Content Read More

NLA 2025: Inclisiran With Standard Care Provides Rapid, Sustained Lowering of LDL-C in Patients With Recent Acute Coronary Syndrome

by MM360 Staff | May 30, 2025 | Myeloma News

Source: Pharmacy Times articles Building on positive low-density lipoprotein cholesterol (LDL-C)-lowering seen in patients with atherosclerotic cardiovascular disease, inclisiran was found to induce meaningful and sustained LDL-C reductions following recent acute...

Proactive Dermatologic Care Reduces Symptom Severity and Boosts Quality of Life in NSCLC

by MM360 Staff | May 30, 2025 | Myeloma News

Source: Pharmacy Times articles Enhanced dermatologic management reduces skin rash and improves quality of life for patients with EGFR-mutant non-small cell lung cancer. Read More

ASCO 2025: Racial Disparities and Advanced Staging in Early-Onset Colorectal Cancer

by MM360 Staff | May 30, 2025 | Myeloma News

Source: Pharmacy Times articles A study of early-onset colorectal cancer found significant racial disparities, with younger patients more frequently diagnosed at advanced stages. Read More

FDA Grants Fast Track Designation to Drug Candidate for Celiac Disease

by MM360 Staff | May 30, 2025 | Myeloma News

Source: Pharmacy Times articles The FDA grants fast track designation to TEV-53408, a promising treatment for celiac disease designed to address gluten intolerance and improve patient outcomes. Read More
« Older Entries
Next Entries »

Recent Content

  • Prognostic and clinicopathological value of prognostic nutritional index in patients with multiple myeloma: a meta-analysis
  • Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses
  • Randomized Phase 3 study of pomalidomide cyclophosphamide dexamethasone versus pomalidomide dexamethasone in relapse or refractory myeloma: an Asian Myeloma Network study (AMN003)
  • (no title)
  • The risk of second primary malignancies in patients receiving T-cell directed therapies for multiple myeloma: a systematic review
  • (no title)
  • Impact of residual clonal plasma cells in S-phase at the time of autologous stem cell transplantation on clinical outcomes
  • (no title)
  • Efficacy and toxicity of treatment of smoldering multiple myeloma: a systematic review and meta-analysis
  • (no title)
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT